On this phase III trial, patients with low-risk oropharyngeal cancer were assigned to receive standard cisplatin-based CRT or radiotherapy plus cetuximab. Compared with the standard of care regimen, cetuximab showed no toxicity benefit, and negatively impacted tumor control.

Read more